oncology » Trang Công Nghệ | Trangcongnghe.vn

Curium Announces Definitive Agreement to Merge with Lantheus

Globe Newswire

Curium Announces Definitive Agreement to Merge with Lantheus

Globenewswire -

European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

Globe Newswire

European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

Globenewswire -

Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers

Globe Newswire

Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers

Globenewswire -

China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis

Globe Newswire

China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis

Globenewswire -

Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026

Globe Newswire

Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026

Globenewswire -

Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England Journal of Medicine

Globe Newswire

Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England Journal of Medicine

Globenewswire -

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer

Globe Newswire

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer

Globenewswire -

XEM THÊM TIN MỚI